Women's Sexual Health Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid

CHARLESTON, South Carolina, July 10 /PRNewswire/ --

- Zestra Laboratories Launches TV Campaign for Zestra(R) Feminine Arousal
Fluid and Announces New Trial-Size Box with Expanded Retail Distribution

- Zestra(R) Large-Scale Multi-Center Clinical Study Results

Zestra Laboratories announced primary results for its large-scale
clinical study examining the potential of its widely available, non-hormonal,
non-prescription Zestra(R) Feminine Arousal Fluid for improving the sexual
experiences of women. This multi-center study, designed and managed by David
M. Ferguson, PhD, MD, FACCP, is a randomized, placebo-controlled,
double-blind, parallel design trial intended to expand on the results of the
Phase 2 type study conducted in 2001. Efficacy assessments included the
widely used, validated subject self-assessment questionnaire, the Female
Sexual Function Index (FSFI). This Phase 3-type study evaluated the efficacy
and safety of Zestra(R) compared to placebo oil in approximately 200 women
diagnosed with acquired mixed interest/ desire/ arousal/ orgasm disorders in
conditions of home use in conjunction with sexual activities.

Of the 296 women screened at 13 research sites, 256 were randomized to
Zestra(R) or placebo. A total of 178 completed the entire study. There were
no serious adverse events (SAEs) associated with study participants' use of
Zestra(R) or placebo oil. Dr. Ferguson said, "The safety profile seen in this
study reconfirms that of the earlier published study: Zestra(R) was well
tolerated."

Analysis of the FSFI questionnaires indicated that Zestra(R) provided a
significant benefit over placebo in the desire and satisfaction domains (P <
0.05), while showing a highly significant (P < 0.005) benefit over placebo in
the arousal domain. Additionally, the total FSFI score showed a significant
improvement over placebo (P < 0.05). These results confirm the arousal and
satisfaction benefits seen in the previous published clinical trial of
Zestra(R). The new, and unexpected result, is the significant benefit in the
desire domain. All of these results can be interpreted as showing that
Zestra(R) is well tolerated and provides desire, arousal, and sexual
satisfaction benefits for a broad, generalized group of women with sexual
difficulties.

"Although the Food and Drug Administration does not require clinical
trials of non-prescription consumer products, Zestra Laboratories elected to
conduct a Phase III-type FDA-quality study to further assess the product's
safety and effectiveness," said Martin Crosby, Zestra's developer. "Our
collaboration with the nation's leading medical and sexual health experts and
our commitment to research demonstrate our intent to advance the science of
female sexual health and provide a meaningful and safe solution for women
today." Despite a decade of prescription pharmaceutical research in female
sexual disorders, and several effective prescription treatments for erectile
dysfunction (ED), there is still no FDA-approved drug treatment for any form
of female sexual dysfunction or disorder.

"Results from the Zestra(R) study will provide important direction for
future studies in women's sexual health," said Dr. Ferguson. "Because the
study has only just concluded, there is a significant amount of additional
valuable information in the database that we will analyze in great detail
over the coming months," he said.

About Zestra(R) Feminine Arousal Fluid (U.S. Patent 6,737,084)

Zestra Laboratories, Inc., a specialty consumer health products company,
is the developer and manufacturer of Zestra(R) Feminine Arousal Fluid, a
patented all-natural formulation of two botanical oils and two extracts. It
is the only consumer product clinically shown to quickly increase female
sexual desire, sensation, arousal and satisfaction. Because Zestra(R) was
specifically designed for the needs of women: it is hormone-free,
paraben-free, and glycerin-free. Zestra(R), which is easy to use and
topically applied, begins increasing female sexual sensation, arousal and
pleasure in three to five minutes. The effects of each application last up to
45 minutes. For complete product information, visit www.zestra.com.

Expanded Retail Distribution of Zestra(R) Feminine Arousal Fluid

"Last year at this time, Zestra(R) Feminine Arousal Fluid was distributed
by 14,000 retail pharmacies including Walgreens, CVS, RiteAid/Brooks/Eckerd
and Duane Reade," says Alan Fink, President of Zestra Laboratories. "Today,
distribution has expanded to more than 35,000 outlets including nearly every
major drug chain, supermarket chain and discount chain in the USA.
Distribution continues expanding at a rapid pace and now includes WalMart."
Fink added, "Zestra(R) enjoys the unique advantage of being the only product
available in retail stores with statistically proven results from
well-designed, placebo-controlled clinical studies conducted by leading
research experts in the field of women's sexual health."

For online purchasing, Zestra(R) is available from the following 
e-commerce retailers: www.drugstore.com, www.walgreens.com, www.cvs.com,
and the AARP Pharmacy Services Product Catalog www.aarppharmacycatalog.com.

To find Zestra(R) at stores near you, enter your Zip Code in the store
locator link: www.zestra.com/StoreLocator/ .

New "Trial-Size" Box

Zestra Laboratories has introduced a 3-Pack "Trial-Size" box of three
Zestra(R) sachets (MSRP US$9.99) to make women's first trial of Zestra(R)
very affordable. Mr. Fink says, "This package augments the current 9-Pack
(MSRP US$24.95) which provides a more economical purchase for dedicated
Zestra(R) consumers. Most retailers are offering both sizes." Product photo
shots are found here: http://www.zestra.com/ZestraBoxPhoto.jpg

New Television Campaign for Zestra(R) Feminine Arousal Fluid

Crosby and Fink announce the launching of a national television campaign
for 15 and 30 second versions of the tasteful Zestra(R) advertisements that
first aired last fall. Cable channels already airing the ads include A&E, E!,
Oxygen, Fox News, TNT, and Court TV. The campaign began Monday July 9, 2007.
Fink says, "This campaign will provide tremendous consumer awareness of our
product and will support the fine retailers who distribute it." Crosby says,
"With the outstanding clinical study results, expansion of our distribution,
and introduction of the 3-pack box, this television campaign should have a
major impact on our sales." The 15-second TV commercial can be viewed here:
http://www.zestra.com/Zestra15Commercial.wmv

Company Contacts:

    Martin Crosby                                   Alan Fink
    Chairman, CEO, and Chief Science Officer        President
    Tel: +1-843-402-0901                            Tel: +1-843-402-0901
    Fax: +1-843-402-0919                            Fax: +1-843-402-0919
    Email: mcrosby@zestra.com                       Email: afink@zestra.com
    Company website: www.zestra.com


    Web site: http://www.zestraforwomen.com
              http://www.zestra.com
              http://www.zestra.com/Zestra15Commercial.wmv